TREATMENTS FOR EGFR MUTATION-POSITIVE (M plus ) NSCLC PATIENTS - A NETWORK META-ANALYSIS (NMA) BY MUTATION TYPE

被引：6
|
作者：
Popat, S. [1 ]
Yang, J. C. H. [2 ]
Lungershausen, J. [3 ]
Griebsch, I [3 ]
Marten, A. [4 ]
Wu, Y. L. [5 ]
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Natl Taiwan Univ, Taipei 10764, Taiwan
[3] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2166
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A615 / A615
页数：1
相关论文
共 50 条
  • [1] Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis
    Popat, Sanjay
    Mok, Tony
    Yang, James Chih-Hsin
    Wu, Yi-Long
    Lungershausen, Juliane
    Stammberger, Uz
    Griebsch, Ingolf
    Fonseca, Tiago
    Paz-Ares, Luis
    LUNG CANCER, 2014, 85 (02) : 230 - 238
  • [2] TREATMENTS FOR EGFR MUTATION POSITIVE NSCLC - A NETWORK META ANALYSIS
    Fonseca, T.
    Lungershausen, J.
    Wallenstein, G.
    Stammberger, U.
    Bertwistle, D.
    Griebsch, I
    VALUE IN HEALTH, 2013, 16 (07) : A396 - A396
  • [3] Osimertinib in EGFR Mutation-Positive Advanced NSCLC
    不详
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1260 - 1261
  • [4] Management of CNS metastases in patients with EGFR mutation-positive NSCLC
    Shetty, Vijith
    Babu, Suresh
    INDIAN JOURNAL OF CANCER, 2019, 56 (05) : 31 - 37
  • [5] The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis
    Lin, Chutong
    Hu, Fengling
    Chu, Hongling
    Ren, Peng
    Ma, Shanwu
    Wang, Jingdi
    Bai, Jie
    Han, Xuan
    Ma, Shaohua
    THORACIC CANCER, 2021, 12 (07) : 1084 - 1095
  • [6] EGFR TKIS IN EGFR MUTATION-POSITIVE NSCLC WITH BRAIN METASTASIS
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [7] A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer
    Yin, Jianqiong
    Huang, Jing
    Ren, Min
    Tang, Rui
    Xie, Linshen
    Xue, Jianxin
    CANCER PATHOGENESIS AND THERAPY, 2025, 3 (02): : 135 - 146
  • [8] EGFR MUTATION-POSITIVE NSCLC: THE SOUTH WALES EXPERIENCE
    Lester, Jason
    ANTICANCER RESEARCH, 2015, 35 (07) : 4297 - 4297
  • [9] Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
    Paz-Ares, Luis
    Soulieres, Denis
    Moecks, Joachim
    Bara, Ilze
    Mok, Tony
    Klughammer, Barbara
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2014, 18 (08) : 1519 - 1539
  • [10] RELAY plus , an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC
    Nishio, M.
    Nishio, K.
    Suzukawa, K.
    Omori, Y.
    Enatsu, S.
    Visseren-Gru, C.
    Nakagawa, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S896 - S896
12345